LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-18. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
=== The analyte is adsorbed onto the electrode surface === Adsorbed species give simple voltammetric responses: ideally, at slow scan rates, there is no peak separation, the peak width is 90mV for a one-electron redox couple, and the peak current and peak area are proportional to scan rate (observing that the peak current is proportional to scan rate proves that the redox species that gives the peak is actually immobilised). The effect of increasing the scan rate can be used to measure the rate of interfacial electron transfer and/or the rates of reactions that are coupltransfer. This technique has been useful to study redox proteins, some of which readily adsorb on various electrode materials, but the theory for biological and non-biological redox molecules is the same (see the page about protein film voltammetry).
=== Early Exploration and late-18th Century Politics === By the early 1700s, traders from South Carolina were visiting the Overhill towns regularly, and following the discovery of Cumberland Gap in 1748, long hunters from Virginia began pouring into the Tennessee Valley. At the outbreak of the French and Indian War in 1754, the Cherokee supported the British, who in return constructed Fort Loudoun in 1756 to protect the Overhill towns from the French and their allies. During the Anglo-Cherokee War, however, the Cherokee attacked the fort and killed its occupants in 1760. A peace expedition to the Overhill towns led by Henry Timberlake passed along the river through what is now Knoxville in December 1761. The Cherokee supported the British during the Revolutionary War, and after the end of the war, North Carolina, which considered the Tennessee Valley part of its territory, deemed Cherokee claims to the region void. North Carolina made plans to cede its Trans-Appalachian territory to the federal government, but decided to open up the lands to settlement first. In 1783, land speculator William Blount and his brother, John Gray Blount, convinced North Carolina to pass a law offering lands in the Tennessee Valley for sale. Later that year, an expedition consisting of James White (1747–1820), James Connor, Robert Love, and Francis Alexander Ramsey, explored the Upper Tennessee Valley, and discovered the future site of Knoxville. Taking advantage of Blount's land-grab act, White took out a claim for the site shortly afterward.
=== Wound healing and fibrosis === In skin wound healing, CCN1 is highly expressed in the granulation tissue by myofibroblasts, which proliferate and rapidly synthesize ECM to maintain tissue integrity and to promote regeneration of parenchymal cells. However, excessive matrix deposition can lead to fibrosis, scarring, and loss of tissue function. In skin wounds, CCN1 accumulates in the granulation tissue as myofibroblasts proliferate, and eventually reaches a sufficiently high level to drive the myofibroblasts themselves into senescence, whereupon these cells cease to proliferate and express matrix-degrading enzymes. Thus, CCN1 limits synthesis and deposition of ECM by myofibroblasts, reducing the risk of fibrosis during wound healing. In addition to skin wound healing, CCN1 expression is elevated in remodeling cardiomyocytes after myocardial infarction, in vascular injury, and in the long bones during fracture repair. Blockade of CCN1 by antibodies inhibits bone fracture healing in mice. In the kidney, CCN1 is expressed in podocytes in normal adult and embryonic glomeruli, but expression is decreased in IgA nephropathy, diabetic nephropathy, and membranous nephropathy, particularly in diseased kidneys with severe mesangial expansion. CYR61 induction of cellular senescence in the kidney is a potential therapy to limit fibrosis.
== Interactions == Elagolix has a number of potential drug interactions with other medications. Elagolix is a substrate of the cytochrome P450 (CYP450) enzyme CYP3A, and inhibitors and inducers of CYP3A4 may alter the metabolism of elagolix and increase or decrease its circulating levels. The strong CYP3A4 inhibitor ketoconazole has been found to increase peak levels of and total exposure to a single 150 mg dose of elagolix by about 2-fold. Paradoxically, rifampin, a strong inducer of CYP3A4 and other CYP450 enzymes, increased peak levels of and total exposure to a single 150 mg dose of elagolix as well. A single dose of rifampin increased peak levels of elagolix by 4.4-fold and total exposure by 5.6-fold, whereas continuous rifampin therapy increased peak levels of elagolix by 2-fold and total exposure by 1.7-fold. The use of elagolix at 200 mg twice per day concomitantly with rifampin is not recommended, whereas the concomitant use of elagolix at 150 mg once per day with rifampin should be limited to 6 months. No significant changes in exposure to elagolix were observed with concomitant administration of rosuvastatin (a substrate of OATP1B1, OATP1B3, and BCRP), sertraline (a moderate inhibitor of CYP2D6 and CYP2B6), or fluconazole (a strong inhibitor of CYP2C19 and a moderate inhibitor of CYP2C9 and CYP3A4). Elagolix is a substrate of the hepatic OATP1B1 transporter. Levels of elagolix have been found to be increased by 78% in people with a genotype characterized by reduced OATP1B1 transporter function.
Corn and sugar cane are C4 plants, whereas the plants used by bees to produce honey, as well as sugar beet, are predominantly C3 plants. Sugars derived from C4 plants alter the isotopic ratio of sugars in honey but do not affect the isotopic ratio of proteins. In unadulterated honey, the carbon isotopic ratios of sugars and proteins are expected to match. Using this method, adulteration levels as low as seven per cent can be detected.
Sources: en.wikipedia.org
== Timeline and list of outbreaks == 1960: Outbreak of Turkey 'X' disease in England, and aflatoxin discovery. 1961: Identified Aspergillus flavus associated with toxicity of groundnuts. 1962: Aflatoxin B and G identified in TLC analysis. Isolation and synthesis of aflatoxins. 1963: Aflatoxin B2, G1, and G2 were identified and chemically characterized as difurocoumarin derivatives. 1965: FDA approved the first regulation on aflatoxins 30 μg/kg. 1966: Milk toxins were designated as AFM1 and AFM2, and AFM1 was detected in milk, urine, kidney, and liver. 1973 Poland: 10 died following the opening of the tomb of Casimir IV Jagiellon, which contained aflatoxin-producing molds. 2004 Kenya: acute outbreak of aflatoxicosis resulting from ingestion of contaminated maize, 125 confirmed deaths. 2005 US: Diamond Pet Foods recalled aflatoxin-contaminated pet food manufactured from corn at their facility in Gaston, South Carolina. 2009–2011 International: Commercial peanut butter, cooking oils (e.g. olive, peanut and sesame oil), and cosmetics were identified as contaminated with aflatoxin. In some instances, liquid chromatography–tandem mass spectrometry (LC–MS/MS), and other analytical methods, revealed that 48–80% of selected product samples contained detectable quantities of aflatoxin. In many of these contaminated food products, the aflatoxin exceeded the safe limits of the U.S. Food and Drug Administration (FDA) or other regulatory agencies. February–March 2013: Romania, Serbia, Croatia imported into western Europe – 2013 aflatoxin contamination. February 2013: Iowa contamination.
== Pharmacokinetics == The pharmacokinetics of ethanol are well characterized by the ADME acronym (absorption, distribution, metabolism, excretion). Besides the dose ingested, factors such as the person's total body water, speed of drinking, the drink's nutritional content, and the contents of the stomach all influence the profile of blood alcohol content (BAC) over time. Breath alcohol content (BrAC) and BAC have similar profile shapes, so most forensic pharmacokinetic calculations can be done with either. Relatively few studies directly compare BrAC and BAC within subjects and characterize the difference in pharmacokinetic parameters. Comparing arterial and venous BAC, arterial BAC is higher during the absorption phase and lower in the postabsorptive declining phase.
Current fields that materials physicists work in include electronic, optical, and magnetic materials, novel materials and structures, quantum phenomena in materials, nonequilibrium physics, and soft condensed matter physics. New experimental and computational tools are constantly improving how materials systems are modeled and studied and are also fields when materials physicists work in. The field is inherently interdisciplinary, and the materials scientists or engineers must be aware and make use of the methods of the physicist, chemist and engineer. Conversely, fields such as life sciences and archaeology can inspire the development of new materials and processes, in bioinspired and paleoinspired approaches. Thus, there remain close relationships with these fields. Conversely, many physicists, chemists and engineers find themselves working in materials science due to the significant overlaps between the fields.
In ophthalmology, choroidal neovascularization is the formation of a microvasculature within the innermost layer of the choroid of the eye. Neovascularization in the eye can cause a type of glaucoma (neovascularization glaucoma) if the new blood vessels' bulk blocks the constant outflow of aqueous humour from inside the eye.
Sources: en.wikipedia.org
As a missile passes through tissue, it decelerates, dissipating and transferring kinetic energy to the tissues. The velocity of the projectile is a more important factor than its mass in determining how much damage is done; kinetic energy increases with the square of the velocity. In addition to injury caused directly by the object that enters the body, penetrating injuries may be associated with secondary injuries, due for example to a blast injury. The path of a projectile can be estimated by imagining a line from the entrance wound to the exit wound, but the actual trajectory may vary due to ricochet or differences in tissue density. In a cut, the discolouration and the swelling of the skin from a blow happens because of the ruptured blood vessels and escape of blood and fluid and other injuries that interrupt the circulation.
== Genome == A chromosome-level genome assembly of Acheta domesticus was reported in 2023, providing the first high-quality genomic resource for this species. The assembled genome provides a reference for studies of insect development, physiology, and the use of crickets as sustainable food and feed. Earlier transcriptomic analyses across life stages supported gene discovery and functional annotation in A. domesticus, enabling investigations of metabolism, immunity, and growth.
== External links == "The Cheminformatics and QSAR Society". Retrieved 2009-05-11. "The 3D QSAR Server". Retrieved 2011-06-18. Verma, Rajeshwar P.; Hansch, Corwin (2007). "Nature Protocols: Development of QSAR models using C-QSAR program". Protocol Exchange. doi:10.1038/nprot.2007.125. Archived from the original on 2007-05-01. Retrieved 2009-05-11. A regression program that has dual databases of over 21,000 QSAR models "QSAR World". Archived from the original on 2009-04-25. Retrieved 2009-05-11. A comprehensive web resource for QSAR modelers Chemoinformatics Tools Archived 2017-07-04 at the Wayback Machine, Drug Theoretics and Cheminformatics Laboratory Multiscale Conceptual Model Figures for QSARs in Biological and Environmental Science
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.